Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01080209 · ClinicalTrials.gov registry record · Phase 2
Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System
A Phase 2 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 215
- Enrollment target
NCT01080209: Completed Phase 2 study, sponsored by Allergan.
NCT01080209 is a Phase 2 study that has completed, run by Allergan. The registered enrollment target is 215 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01080209, a Phase 2 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 215 participants
- Enrollment target
Study Summary
This study will evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.
Primary Outcome
Implants administered during the parent study are evaluated during this study to determine if they have completely degraded. The time frame is evaluated from the point of the first treatment in the parent study.
Interventions
- OTHER Sham
- DRUG Brimo PS DDS®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 2010-02 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
What the finished NCT01080209 record still lists
NCT01080209 is an interventional study that assigns participants to a tested intervention. The registered 215 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% higher).
The record links to 0 conditions, and to 2 interventions - of which Sham is the first listed.
NCT01080209 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01080209 about?
NCT01080209 is a clinical study titled "Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System". This study will evaluate the biodegradation of the brimonidine tartrate posterior segment drug delivery system.
What is the current status of trial NCT01080209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 2010-02. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01080209?
The interventions under investigation include: Sham (OTHER), Brimo PS DDS® (DRUG).
Who is sponsoring clinical trial NCT01080209?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01080209's enrollment target sits among peer trials
215 289th of 2000 higher than 1,711 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05134012 · 215 participants · Phase 3
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
- NCT05169970 · 215 participants · Phase 2
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
- NCT05197270 · 215 participants · Phase 1
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- NCT05230199 · 215 participants · NA
Sensory Optimization of the Hospital Environment
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia